literature

HIV mutation literature information.

The HIV type 1 protease L10I minor mutation decreases replication capacity and confers resistance to protease inhibitors.

PMID: 21142921 2011 AIDS research and human retroviruses

Abstract: Furthermore, viruses carrying the major mutation D30N or the minor mutation L10I showed a significant decrease in RC (p-value <0.05), whereas viruses carrying the minor mutation L63P had RC similar to wild-type virus.

Abstract: We characterized the HIV protease minor mutations, L10I, compared to the minor mutation, L63P, and the major mutation D30N and their impact on viral fitness and resistance to protease inhibitors.

Identification of amino acids within the second alpha helical domain of the human immunodeficiency virus type 1 Vpu that are critical for preventing CD4 cell surface expression.

PMID: 19944437 2010 Virology

Discussion: In their studies, mutation of the conserved leucine at position 63 to a proline or mutation of residues from position 65 to 70 to alanines affected CD4 degradation, without altering Vpu-CD4 interactions.

Discussion: The protein structure programs used in this study showed that L63P resulted in a shorter predicted alpha-helical domain while the substitution of six residues at positions 65-70 extended the alpha-helical domain (data not shown).

Prevalence of drug resistance and associated mutations in a population of Hiv-1+ Puerto Ricans in 2005.

PMID: 23875516 2010 Boletin de la Asociacion Medica de Puerto Rico

Abstract: Protease mutations with the highest rate of expression were L63P, M361 and L90M.

Introduction: The highest mutation frequencies were M184V for RT inhibitor resistance and L63P for PI resistance.

Result: As shown in Table III, the PI resistance-associated specific mutations with the highest degree of expression for 2005 were L63P (73.6%), M36I (26.2%), and L90M (21.0%).

In Vivo validation of a bioinformatics based tool to identify reduced replication capacity in HIV-1.

PMID: 21603285 2010 The open medical informatics journal

Discussion: In people infected with clade B strains of HIV, those that harbor virus containing the D30N mutation often also have the L63P mutation.

Discussion: Moreover, others have reported that the replication of a D30N containing variant was not significantly different from a L63P+D30N dual mutant.

Discussion: The L63P mutation was not identified as having a large fitness defect by our model, likely because the L63P mutation is prevalent in patients who are treatment naive and is therefore not a drug-resistance mutation.

Patients with discordant responses to antiretroviral therapy have impaired killing of HIV-infected T cells.

PMID: 21124822 2010 PLoS pathogens

Method: K20R sense: 5'-GGGCAACTAAGGGAAGCTCTA-3', anti-sense: 5'-TAGAGCTTCCCTTAGTTGCCC-3'; D25G sense: 5'-AGGAAGCTCTATTAGGTACAGGAGCAGATGA-3', anti-sense: 5'-TCATCTGCTCCTGTACCTAATAGAGCTTCCT; T26S sense: 5'-GAAGCTCTATTAGATAGTGGAGCAGATGATACA-3'; anti-sense: 5'-TGTATCATCTGCTCCACTATCTAATAGAGCTTC-3'; I54V sense: 5'-GGAATTGGAGGTCTTATCAAAGTAAGA-3; anti-sense: 5'-TCTTACTTTGATAAGACCTCCAATTCC-3'; I54V sense: 5'-ATTGGAGGTTTTGTCAAAGTAAGACAG-3', anti-sense: 5

Discussion: Indeed the combined effect of mutations which impair protease cytotoxic effects (e.g., I54V and V82A) along with other mutations that do not (e.g., L63P, L90M) will need to be individually assessed.

[Prevalence of primary antiretroviral resistance among HIV infected patients in Chile].

PMID: 20919475 2010 Revista medica de Chile

Abstract: Of these, the most common were L63P/T (38 patients), L10I/V (27 patients) and V77I (26 patients).

Prevalence and clinical significance of HIV drug resistance mutations by ultra-deep sequencing in antiretroviral-naive subjects in the CASTLE study.

PMID: 20532178 2010 PloS one

Table: L63P

HIV-1 protease inhibitors with a transition-state mimic comprising a tertiary alcohol: improved antiviral activity in cells.

PMID: 19961222 2010 Journal of medicinal chemistry

Abstract: The synthesis of 25 new and optically pure HIV-1 protease inhibitors is reported, along with methods for elongation of the inhibitor P1' side chain using microwave-accelerated, palladium-catalyzed cross-coupling reactions, the biological evaluation, and X-ray data obtained from one of the most potent analogues cocrystallized with both the wild type and the L63P, V82T, I84 V mutant of the HIV-1 protease.

Analysis and characterization of dimerization inhibition of a multi-drug-resistant human immunodeficiency virus type 1 protease using a novel size-exclusion chromatographic approach.

PMID: 19149765 2009 The Biochemical journal

Result: PRMDR contains multiple drug-resistant mutations (L10I, K45R, I54V, L63P, A71V, V82T, L90M and I93L) and is highly resistant to a number of active-site inhibitors, although it remains sensitive to the experimental active-site inhibitor JE-2147.

Rapid and persistent selection of the K103N mutation as a majority quasispecies in a HIV1-patient exposed to efavirenz for three weeks: a case report and review of the literature.

PMID: 21092074 2009 Journal of medical case reports

Table: L63P

Browser Board

Co-occurred Entities

Filtrator